A novel sustained-release formulation of buprenorphine (CAM2038) blocked the euphoric effects of illicit opioids and suppressed withdrawal in patients with opioid use disorder (OUD), according to a study published in JAMA Psychiatry. Weekly subcutaneous buprenorphine injections may prevent the misuse, diversion, and nonadherence associated with the current daily sublingual buprenorphine formulation, wrote the researchers.
Slomski A. Injectable Buprenorphine Halts Effects of Opioids and May Deter Abuse. JAMA. 2017;318(12):1099. doi:10.1001/jama.2017.14120
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: